ReviewCurrent oncology reports2022
Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?
Review in Current oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.Endocrine-related cancer · 2026Guideline
- [Rectal neuroendocrine tumors of the rectum: update on endoscopic and surgical treatment].Chirurgie (Heidelberg, Germany) · 2026Review
- Tumor count and risk of lymph node metastasis in multiple rectal neuroendocrine tumors: an individual-level pooled analysis.World journal of surgical oncology · 2026Article
- Article
- Clinical Outcomes of Peptide Receptor Radionuclide Therapy in Japanese Patients with Metastatic Rectal Neuroendocrine Tumors.Cancers · 2026Article
- Long-Term Outcomes after the Complete Resection of Rectal Neuroendocrine Tumors: A Multicenter Cohort Study.Gut and liver · 2026Article
- Clinicopathological Characteristics and Survival Outcomes of Gastrointestinal Neuroendocrine Tumors in a Large Safety Net Hospital.Journal of clinical medicine · 2026Article
- Risk Factors for Rectal Neuroendocrine Tumors: A Population-Based Cohort Study of Sex-Specific Associations.Digestive diseases (Basel, Switzerland) · 2026Article
- Artificial intelligence-assisted diagnosis of rectal neuroendocrine tumors during white-light endoscopy.World journal of gastroenterology · 2025Article
- Rectal Neuroendocrine Tumor With Non-Atypical Mucous Cell Glands: A Case Report.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Incidence trends and relative survival of colorectal neuroendocrine neoplasms: A population-based study using German cancer registry data.International journal of cancer · 2025Article
- Transanal endoscopic microsurgery in the treatment of rectal neuroendocrine tumors: a retrospective 10-year single-center experience.Langenbeck's archives of surgery · 2025Article
- An Update on the Management of Rectal Neuroendocrine Neoplasms.Current treatment options in oncology · 2024Review
- Association Between Female Sex and Better Survival in Gastroenteropancreatic Neuroendocrine Tumors.The Journal of surgical research · 2024Article
- Effective utilization of polypectomy in endoscopic salvage treatment of rectal neuroendocrine tumors: a retrospective cohort study.Annals of surgical treatment and research · 2024Article
- Geographical Variations in Early Onset Colorectal Cancer in the United States between 2001 and 2020.Cancers · 2024Article
- Risk of metastasis and survival in patients undergoing different treatment strategies with T1 colonic neuroendocrine tumors.Journal of endocrinological investigation · 2024Article
- Early-Onset Colorectal Cancer: Are Neuroendocrine Tumors or Adenocarcinomas the Culprit? Analysis of the Largest U.S. Cancer Incidence Database, 2001-2020.Journal of clinical medicine · 2024Article
- Resection of the primary tumor improves the prognosis of gastrointestinal neuroendocrine neoplasms with liver metastases: mutual validation based on SEER database and institutional data.BMC gastroenterology · 2023Article
- The Incidence of Rectal Neuroendocrine Tumors Is Increasing in Younger Adults in the US, 2001-2020.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review examines the variation in incidence of rectal neuroendocrine tumours across the globe. Rectal neuroendocrine tumours are a common type of gastrointestinal NET with an increasing incidence reported over the last 30 years. RECENT
findingsThere have been a number of publications examining the epidemiology of neuroendocrine tumours across the world. These have utilized a variety of different methodologies to examine both incidence of prevalence of NETs. We review the data published and describe any causative factors and findings regarding the epidemiology of rectal NETs. Rectal NETs account for 1-2% of all rectal cancers and are commonly diagnosed between 50-60 years of age. Most lesions are identified by chance at colonoscopy, commonly during colon cancer screening procedures, which is reflected in part in the age at diagnosis. Most lesions are small in size, < 10 mm and can be managed with endoscopic resection rather than requiring surgery. The highest incidence is reported in people of Asian ethnicity, with a tenfold increased incidence reported in some series compared with white population. There is also an increased incidence in Black and Hispanic population as identified through the Surveillance, Epidemiology and End Results (SEER) database. Endoscopic assessment of lesions is variable globally. Future work to better understand the cause of ethnic variation and development of comprehensive cancer registries would be helpful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.